Listed

Protalix BioTherapeutics, Inc.: Form 10-Q/A for the period ended Sep 30, 2018

Filed with the SEC on Mar 18, 2019 and accepted by EDGAR at Mar 18, 2019, 07:20 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Cost of revenue3 months2018-07-01 to 2018-09-30$1.9mus-gaap:CostOfRevenue
Cost of revenue9 months2018-01-01 to 2018-09-30$7.0mus-gaap:CostOfRevenue
Research and development3 months2018-07-01 to 2018-09-30$10.8mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2018-01-01 to 2018-09-30$25.6mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2018-07-01 to 2018-09-30$4.1mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative9 months2018-01-01 to 2018-09-30$8.7mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2018-07-01 to 2018-09-30−$3.7mus-gaap:OperatingIncomeLoss
Operating income9 months2018-01-01 to 2018-09-30−$15.6mus-gaap:OperatingIncomeLoss
Net income3 months2018-07-01 to 2018-09-30−$5.3mus-gaap:NetIncomeLoss
Net income9 months2018-01-01 to 2018-09-30−$21.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-07-01 to 2018-09-30−$0.04us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS9 months2018-01-01 to 2018-09-30−$0.14us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow9 months2018-01-01 to 2018-09-30−$3.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2018-01-01 to 2018-09-30$498.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2018-09-30$41.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-09-30$57.3mus-gaap:AssetsCurrent
Total assetsAt period end2018-09-30$65.7mus-gaap:Assets
Current liabilitiesAt period end2018-09-30$24.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2018-09-30$113.7mus-gaap:Liabilities
Shareholders' equityAt period end2018-09-30−$47.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-19-014455. Last ingested by Listed: Nov 10, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.